US health body grants $67.5 million for pandemic readiness

19 May 2022

In the USA, the National Institute of Allergy and Infectious Diseases (NIAID) has awarded $67.5 million to a consortium of researchers working on pandemic preparedness.

As the coronavirus pandemic continues to be felt around the world, the White House and federal agencies in the country are eager to ensure that future pandemic threats are addressed in a more effective way.

The money will be used by scientists at the UC San Francisco (UCSF) Quantitative Biosciences Institute (QBI) and the QBI Coronavirus Research Group (QCRG), and will cover an initial three-year period.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK